Chwilio Deddfwriaeth

Chwiliad Uwch

Regulation (EC) No 1394/2007 of the European Parliament and of the CouncilDangos y teitl llawn

Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance)

Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

Mae hon yn eitem o ddeddfwriaeth sy’n deillio o’r UE

Mae unrhyw newidiadau sydd wedi cael eu gwneud yn barod gan y tîm yn ymddangos yn y cynnwys a chyfeirir atynt gydag anodiadau.Ar ôl y diwrnod ymadael bydd tair fersiwn o’r ddeddfwriaeth yma i’w gwirio at ddibenion gwahanol. Y fersiwn legislation.gov.uk yw’r fersiwn sy’n weithredol yn y Deyrnas Unedig. Y Fersiwn UE sydd ar EUR-lex ar hyn o bryd yw’r fersiwn sy’n weithredol yn yr UE h.y. efallai y bydd arnoch angen y fersiwn hon os byddwch yn gweithredu busnes yn yr UE. EUR-Lex Y fersiwn yn yr archif ar y we yw’r fersiwn swyddogol o’r ddeddfwriaeth fel yr oedd ar y diwrnod ymadael cyn cael ei chyhoeddi ar legislation.gov.uk ac unrhyw newidiadau ac effeithiau a weithredwyd yn y Deyrnas Unedig wedyn. Mae’r archif ar y we hefyd yn cynnwys cyfraith achos a ffurfiau mewn ieithoedd eraill o EUR-Lex. The EU Exit Web Archive legislation_originated_from_EU_p3

Changes to legislation:

There are outstanding changes not yet made to Regulation (EC) No 1394/2007 of the European Parliament and of the Council. Those changes will be listed when you open the content using the Table of Contents below. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. Help about Changes to Legislation

Close

Changes to Legislation

Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.

  1. Introductory Text

  2. CHAPTER 1 SUBJECT MATTER AND DEFINITIONS

    1. Article 1.Subject matter

    2. Article 2.Definitions

  3. CHAPTER 2 MARKETING AUTHORISATION REQUIREMENTS

    1. Article 3.Donation, procurement and testing

    2. Article 4.Clinical trials

    3. Article 5.Good manufacturing practice

    4. Article 6.Issues specific to medical devices

    5. Article 7.Specific requirements for advanced therapy medicinal products containing devices

  4. CHAPTER 3 MARKETING AUTHORISATION PROCEDURE

    1. Article 8.Evaluation procedure

    2. Article 9.Combined advanced therapy medicinal products

  5. CHAPTER 4 SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET

    1. Article 10.Summary of product characteristics

    2. Article 11.Labelling of outer/immediate packaging

    3. Article 12.Special immediate packaging

    4. Article 13.Package leaflet

  6. CHAPTER 5 POST-AUTHORISATION REQUIREMENTS

    1. Article 14.Post-authorisation follow-up of efficacy and adverse reactions, and risk management

    2. Article 15.Traceability

  7. CHAPTER 6 INCENTIVES

    1. Article 16.Scientific advice

    2. Article 17.Scientific recommendation on advanced therapy classification

    3. Article 18.Certification of quality and non-clinical data

    4. Article 19.Reduction of the fee for marketing authorisation

  8. CHAPTER 7 COMMITTEE FOR ADVANCED THERAPIES

    1. Article 20.Committee for Advanced Therapies

    2. Article 21.Composition of the Committee for Advanced Therapies

    3. Article 22.Conflicts of interest

    4. Article 23.Tasks of the Committee for Advanced Therapies

  9. CHAPTER 8 GENERAL AND FINAL PROVISIONS

    1. Article 24. Amendments to the Annexes

    2. Article 25.Report and review

    3. Article 25a. Exercise of the delegation

    4. Article 26.Committee procedure

    5. Article 27.Amendments to Regulation (EC) No 726/2004

    6. Article 28.Amendments to Directive 2001/83/EC

    7. Article 29.Transitional period

    8. Article 30.Entry into force

  10. Signature

    1. ANNEX I

      Manipulations referred to in the first indent of Article 2(1)(c)

      1. cutting, grinding, shaping, centrifugation, soaking in antibiotic or antimicrobial solutions,...

    2. ANNEX II

      Summary of product characteristics referred to in Article 10

      1. 1. Name of the medicinal product.

      2. 2. Composition of the product:

        2. 2.1. general description of the product, if necessary with explanatory drawings...

        3. 2.2. qualitative and quantitative composition in terms of the active substances...

      3. 3. Pharmaceutical form.

      4. 4. Clinical particulars:

        2. 4.1. therapeutic indications,

        3. 4.2. posology and detailed instructions for use, application, implantation or administration...

        4. 4.3. contra-indications,

        5. 4.4. special warnings and precautions for use, including any special precautions...

        6. 4.5. interaction with other medicinal products and other forms of interactions,...

        7. 4.6. use during pregnancy and lactation,

        8. 4.7. effects on ability to drive and to use machines,

        9. 4.8. undesirable effects,

        10. 4.9. overdose (symptoms, emergency procedures).

      5. 5. Pharmacological properties:

        2. 5.1. pharmacodynamic properties,

        3. 5.2. pharmacokinetic properties,

        4. 5.3. preclinical safety data.

      6. 6. Quality particulars:

        2. 6.1. list of excipients, including preservative systems,

        3. 6.2. incompatibilities,

        4. 6.3. shelf life, when necessary after reconstitution of the medicinal product...

        5. 6.4. special precautions for storage,

        6. 6.5. nature and contents of container and special equipment for use,...

        7. 6.6. special precautions and instructions for handling and disposal of a...

      7. 7. Marketing authorisation holder.

      8. 8. Marketing authorisation number(s).

      9. 9. Date of the first authorisation or renewal of the authorisation....

      10. 10. Date of revision of the text.

    3. ANNEX III

      Labelling of outer/immediate packaging referred to in Article 11

      1. The name of the medicinal product and, if appropriate, an...

    4. ANNEX IV

      Package leaflet referred to in Article 13

      1. For the identification of the advanced therapy medicinal product: the...

Yn ôl i’r brig

Options/Help

Print Options

Close

Mae deddfwriaeth ar gael mewn fersiynau gwahanol:

Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.

Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE): Mae'r wreiddiol version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Pwynt Penodol mewn Amser: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.

Close

Dewisiadau Agor

Dewisiadau gwahanol i agor deddfwriaeth er mwyn gweld rhagor o gynnwys ar y sgrin ar yr un pryd

Close

Rhagor o Adnoddau

Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted version that was used for the EU Official Journal
  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • pob fformat o’r holl ddogfennau cysylltiedig
  • slipiau cywiro
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Close

Llinell Amser Newidiadau

Mae’r llinell amser yma yn dangos y fersiynau gwahanol a gymerwyd o EUR-Lex yn ogystal ag unrhyw fersiynau dilynol a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig.

Cymerir dyddiadau fersiynau’r UE o ddyddiadau’r dogfennau ar EUR-Lex ac efallai na fyddant yn cyfateb â’r adeg pan ddaeth y newidiadau i rym ar gyfer y ddogfen.

Ar gyfer unrhyw fersiynau a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig, bydd y dyddiad yn cyd-fynd â’r dyddiad cynharaf y daeth y newid (e.e. ychwanegiad, diddymiad neu gyfnewidiad) a weithredwyd i rym. Am ragor o wybodaeth gweler ein canllaw i ddeddfwriaeth ddiwygiedig ar Ddeall Deddfwriaeth.

Close

Rhagor o Adnoddau

Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted fersiwn a ddefnyddiwyd am y copi print
  • slipiau cywiro

liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys

  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • manylion rhoi grym a newid cyffredinol
  • pob fformat o’r holl ddogfennau cysylltiedig
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill